Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

BACKGROUND: Facial redness contributes to impaired psychosocial functioning in rosacea patients and the only approved treatment for erythema is topical brimonidine gel 0.33%. OBJECTIVES: To evaluate patient‐reported outcomes, as well as efficacy and safety, in subjects with self‐perceived severe ery...

Descripción completa

Detalles Bibliográficos
Autores principales: Layton, A.M., Schaller, M., Homey, B., Hofmann, M.A., Bewley, A.P., Lehmann, P., Nohlgård, C., Sarwer, D.B., Kerrouche, N., Ma, Y.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054962/
https://www.ncbi.nlm.nih.gov/pubmed/26416154
http://dx.doi.org/10.1111/jdv.13305

Ejemplares similares

Ejemplares similares